ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal...

Area of Science:

• Oncology
• Immunotherapy
• Surgical Oncology

Background:

• Peritoneal metastasis from colorectal cancer (PM-CRC) presents a significant therapeutic challenge.
• Intraperitoneal MOC31PE immunotoxin is investigated as a novel treatment strategy for PM-CRC.
• The ImmunoPeCa trial reports long-term outcomes of this therapeutic approach.

Purpose of the Study:

• To evaluate the safety and toxicity of intraperitoneal MOC31PE immunotoxin in patients with PM-CRC undergoing CRS-HIPEC.
• To assess the long-term overall survival (OS) and disease-free survival (DFS) as secondary endpoints.
• To explore the potential of MOC31PE as a targeted therapy for peritoneal carcinomatosis.

Main Methods:

• A dose-finding trial design was employed.
• Twenty-one patients with PM-CRC received intraperitoneal MOC31PE at four dose levels post-CRS-HIPEC with mitomycin C.
• Safety, toxicity, OS, and DFS were evaluated, with an expansion cohort included.

Main Results:

• With a median follow-up of 31 months, the 3-year OS was 78% and 3-year DFS was 33%.
• Median OS was not reached.
• Excluding patients with favorable characteristics showed a median DFS of 13 months and 3-year OS of 72%.

Conclusions:

• The promising long-term outcomes suggest MOC31PE immunotoxin warrants further clinical investigation.
• Low systemic absorption and high peritoneal drug concentration support its potential efficacy.
• Further studies are recommended to confirm the clinical benefit of MOC31PE in PM-CRC treatment.